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Abstract 
    Background. The proxy-marker for human papillomavirus (HPV), p16, is included in the new 
AJCC8
th
/UICC8
th
 staging system, but due to incongruence between p16-status and HPV-infection, 
single biomarker evaluation could lead to misallocation of patients. We established nomograms for 
overall- (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous cell 
carcinoma (OPSCC) and known HPV-DNA and p16-status, and validated the models in cohorts 
from high and low prevalent HPV-countries. 
    Methods. Consecutive OPSCC patients treated in Denmark, 2000-2014 formed the development 
cohort. The validation cohorts were from Sweden, Germany, and the UK. We developed 
nomograms by applying a backward selection procedure for selection of variables, and assessed 
model performance.  
   Results. In the development cohort 1,313 patients, and in the validation cohorts 344 German, 503 
Swedish, and 463 British patients, were included. For the OS nomogram, age, gender, combined 
HPV-DNA and p16-status, smoking, T-, N-, and M-status, and UICC-8 staging were selected, and 
for the PFS nomogram the same variables except UICC-8 staging. The nomograms performed well 
in discrimination and calibration. 
    Conclusion. Our nomograms are reliable prognostic methods in patients with OPSCC. 
Combining HPV-DNA and p16 is essential for correct prognostication. The nomograms are 
available at www.orograms.org.  
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Introduction 
    In most parts of the Western world, the main risk factor for oropharyngeal squamous cell 
carcinoma (OPSCC) is now infection with high-risk human papillomavirus (HPV); while, a smaller 
proportion is related to a high consumption of alcohol and smoking tobacco (Mellin et al, 2000a; 
Wittekindt et al, 2011; Schache et al, 2016; Carlander et al, 2017). Patients with HPV-associated 
OPSCCs have improved survival probably related to a different mutational profile (Hayes et al, 
2015; Lawrence et al, 2015), immune response (Nasman et al, 2013; Nordfors et al, 2013a; Saber et 
al, 2016), and clinical features (Marur et al, 2010).  
    p16-overexpression is a proxy marker for HPV-driven carcinogenesis which is the main 
prognostic factor in patients with OPSCC. Consequently, p16 was included in the newly proposed 
American Joint Committee on Cancer/Union for International Cancer Control (AJCC-8/UICC-8) 
staging system. However, an estimated 10-20% of all OPSCCs are p16-positive, but HPV-negative, 
due to alternative cellular events leading to p16-overexpression (Wang et al, 2013; Mirghani et al, 
2016) being most apparent in oropharyngeal non-tonsillar, non-base of tongue cancer (Marklund et 
al, 2012). Hence, it may be suboptimal to stratify patients based on evaluation of a single biomarker 
(i.e. p16 alone) due to the risk of misclassification of tumours and thereby misallocation of patients 
with an undesired prognosis (Chung et al, 2014; Seiwert, 2014). The combination of HPV-DNA 
and p16-status has shown better prognostication (Garnaes et al, 2016). Available nomograms so far 
for patients with OPSCC do not include combined HPV-DNA and p16 status, and models have not 
been externally validated across areas with high and low HPV-prevalence (Rios Velazquez et al, 
2014; Fakhry et al, 2017).  
    A nomogram is a graphical illustration of a statistical model for calculating the cumulative effect 
of several variables on a particular outcome, and nomograms have been developed to predict 
clinical end-points for patients with several types of malignancies. In this study we aimed to 
identify OPSCC- and patient-related factors associated with OS and PFS, and to construct and 
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externally validate predictive nomograms. Moreover, this is the first study addressing patients 
treated for an OPSCC encompassing high and low HPV-prevalent countries in validation cohorts, 
and incorporating the newly published AJCC-8/UICC-8 staging system refining prognostication by 
employing both HPV-DNA and p16 status.  
 
Materials and Methods 
Patient cohorts and determination of p16 overexpression and presence of HPV DNA 
The development cohort. Consecutive patients diagnosed with OPSCC and treated with curative 
intent in Eastern Denmark between 2000-2014 were included in the development cohort (Garnaes et 
al, 2014, 2015; Carlander et al, 2017). Using the unique resident-code from the Danish Civil 
Registration System, we linked the Danish Head and Neck Cancer Group (DAHANCA) (Danish 
Head and Neck Cancer Group (DAHANCA)) database and the Danish Pathology Data Registry 
(DPDR), (Bjerregaard & Larsen, 2011) to identify patients. Patient characteristics were retrieved 
from these databases as well as from medical records. Curative radiotherapy regimens consisted of 
66-68 GY, divided into 33-34 fractions given 6 days a week. From 2007, stage III-IV (UICC 7
th
) 
patients were offered concurrent chemotherapy (primarily weekly cisplatin 40mg/sqm), if tolerated, 
whilst a minority were treated with cetuximab.  
    An expert head and neck pathologist re-validated a hematoxylin-eosin (H&E)-stained section of 
each tumour. p16-staining was considered positive if there was a strong and diffuse nuclear and 
cytoplasmic reaction in more than 70% of the tumour cells (Grønhøj Larsen et al, 2014). 
Immunohistochemistry for p16 was done using the Ventana Benchmark Ultra autostainer with the 
UltraView detection kit and the p16 monoclonal antibody E6H4 ready-to-use with CC1 as a 
pretreatment (Roche, Tuscon, USA).  
     DNA was isolated from two to four 10-μm sections using the DSP DNA Mini Kit and the 
QIAsymphony SP kit (Qiagen, Hilden Germany), according to the manufacturers’ instructions.  
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HPV DNA PCR was done using the general primers GP5+/6+ and Platinum Taq DNA polymerase 
(Invitrogen, Naerum, Denmark). All GP5+/6+ PCR negative samples were subject to a GAPDH 
(housekeeping gene) PCR to confirm DNA quality. HPV DNA amplicons were run on the QIAxcel 
Advanced System using the QX DNA Screening Gel (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. The expected amplicon sizes were approximately 150 base pairs (bp) 
for GP5+/6+ and 200 bp for GAPDH. Negative samples were resolved on a 2.5% agarose gel 
stained with ethidium bromide to compare the sensitivity of the current assay with the standard. 
Approximately 50% of all samples were analysed by HPV PCR and sequenced (Carlander et al, 
2017) and the remaining samples were analysed by HPV-PCR (Garnaes et al, 2014, 2015). 
The validation cohorts. Three independent cohorts formed the external validation cohorts. The 
populations consisted of patients with OPSCC treated with curative intent at Karolinska University 
Hospital (Stockholm, Sweden; 2005-2012), Giessen University Hospital (Giessen, Germany; 2000-
2009), and The Predictr Consortium, United Kingdom (UK) (2001-2012). 
    The Swedish cohort was classified using p16 immunohistochemistry (clone JC8, dilution 1:100, 
Santa Cruz Biotechnology, CA, USA or clone E6H4, DakoCytomation A/S, Carpinteria, CA, USA) 
and  high-risk HPV-DNA detection by a bead-based multiplex assay on a Magpix instrument 
(LUMINEX Inc, Austin, TX, USA) (Nordfors et al, 2013b). The Magpix instrument is known to 
amplify the 27 HPV types: HPV 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 
58, 59, 66, 67, 68, 69, 70, 73 and 82. 
    The German cohort was classified using p16 immunohistochemistry (CINtec histology, Roche 
mtm laboratories) and high-risk HPV-DNA detection by PCR followed by bead-based hybridisation 
(Luminex Technology, Multimetrix, Progen, Heidelberg, Germany) (Wagner et al, 2017). The 
Luminex technology is known to amplify the HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73, and 82), three putative high-risk types (26, 53, and 66), and six low-risk types (6, 11, 42, 
43, 44, and 70. 
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    The UK cohort was classified using p16 immunohistochemistry (CINtec histology, Roche mtm 
laboratories) and high risk HPV DNA in situ hybridisation (Inform HPV III, Ventana Medical 
Systems Inc) (Schache et al, 2016). INFORM HPV III Family 16 probe B detects HPV-16, -18, -31, 
-33, -35, -39, -45, -51, -52, -56, -58, and 66.  
The GP5+/GP6+ primers(De Roda Husman et al, 1995) are known to amplify at least 37 mucosal 
HPV types(Schmitt et al, 2008), namely 14 high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68, and 23 low-risk HPV types 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 
70, 71, 72, 73, 81, 82/MM4, 82/IS39, 83, 84, and 89. The specific HPV types can then be identified 
by e.g. sequencing of the resulting amplicons(Carlander et al, 2017). 
    Overexpression of p16 (>70% positive staining) was classified similar to the Danish cohort for 
all three validations cohorts. Treatment modality for the validation cohorts are presented in more 
detail in Table 1. 
 
Statistics  
Covariates available for adjustment are described in Table 1. Age was included as a continuous 
variable in the analyses, and the remaining variables were included as categorical variables. Overall 
survival (OS) was defined as the time from diagnosis of OPSCC to death from any cause. 
Progression was based on a biopsy or relevant imaging and progression-free survival (PFS) was 
defined as the time from diagnosis of OPSCC to time of progression at any site or death from any 
cause. Patients were censored at the last date of follow-up, or administratively censored five years 
after diagnosis. Kaplan-Meier curves were used to illustrate survival differences and significant 
differences were assessed with log-rank tests.  
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    To evaluate which covariates influenced survival, we fitted multivariate Cox regression analyses 
with all factors in Table 1 except treatment included (full model), ties were handled with the 
method suggested by Efron. Subsequently, we simplified the full models using a stepwise backward 
elimination procedure with Akaike’s Information Criteria as stopping criteria (final model) using 
the R package rms and the function fastbw (Harrell, 2001). All models are multivariable, i.e. factors 
are mutually adjusted, and thus the effect estimates can not be interpreted marginally. In a 
subanalysis, we evaluated the effect of fitting a spline for age in the development model. These sub 
analysis showed for the none-linear part of the spline is none-significant; e.g. OS (p=0.92) and PFS 
(p=0.85).  
To test whether the assumption of proportional hazards was violated, we tested for trends in the 
scaled Schoenfeld residuals of the final models (Grambsch & Therneau, 1994). None of the final 
models violated the proportional hazards assumption. Based on the final models, nomograms were 
constructed to predict overall survival and progression-free survival at 1, 3, and 5 years after 
diagnosis. We only considered complete cases (e.g. patients were excluded from the analysis in the 
case of missing information from one or more variables). p values less than 5% were considered 
significant and all analyses were performed in R version 3.0.3 (R Development Core Team, 2016). 
Validation and calibration of multivariate cox regression models 
We conducted external validation by applying our nomograms to the patient cohorts from Sweden, 
UK, and Germany. We assessed nomogram model performance by examining overall accuracy 
(Brier score), (BRIER, 1950) calibration plots, (Hosmer et al, 1997) and discrimination (Harrell’s C 
index) (Harrell et al, 1996). In addition, we fitted a Weibull calibration model as suggested by van 
Houwelingen and Putter in which shifts in baseline cumulative hazard (obtained from the final Cox-
models), the effect of the prognostic index (the linear predictor in the Cox-model) and the shape of 
the cumulative baseline hazard were tested (Houwelingen & Putter, 2012). A smoothed version of 
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the cumulative baseline hazard was used in the calibration model, where smoothing was done by 
linear interpolation. 
 
Results 
Population demographics 
The development cohort consisted of 1,313 patients with a total of 457 deaths (35%) during follow-
up (Table 1). The majority of patients were males (72%), with a median age of 59.8 years at 
diagnosis, and had most frequently HPV+/p16+ tumors (58%). Patients typically presented with 
tumours in advanced nodal stage (78% with N+), with small primary tumours (68% T1 or T2), and 
in early UICC8 stage (65% UICC8 stage I or II). OS was for the HPV+/p16+ patients 95% (95% CI 
93-96%) after 1 year, 86% (95% CI 84-89%) after 3 years, and 80% (95% CI 77–83%) after 5 years 
follow-up, and for the HPV-/p16- patients 71% (95% CI 65-74%) after 1 year, 46% (95% CI 41-
51%) after 3 years, and 34% (95% CI 29-39%) after 5 years (Figure 1, Table 2). Demographic 
information and treatment modality for the validation cohorts is shown in Table 1.  
 
Overall survival 
Five-year OS for the HPV+/p16+ patients in the Swedish cohort were 81% (95% CI 77–85%) and 
for the HPV-/p16- patients 40% (95% CI 31-52%); for the German cohort 81% (95% CI 72–91%) 
and 35% (95% CI 30-42%); and in UK cohort were 82% (95% CI 77–87%) and 42% (95% CI 34-
52%) (Figure 1, Table 2, Suppl. Table S1). 
   The backwards elimination procedure left the model for overall survival unchanged, i.e. the model 
included age, gender, combined HPV and p16 status, smoking, T-, N-, and M-classification, and 
UICC-8 staging (Table 3). The OS nomogram was used to predict the probability of death due to 
any cause at 1-, 3-, and 5 years after diagnosis (Figure 2).  
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     Figure 3 shows the calibration plots for internal and external validation at 1- , 3-, and 5 years. 
The calibration model showed that the log cumulative baseline hazard was shifted by -0.51 (95% 
CI: -0.75 to – 0.26) in the Swedish cohort, -0.35 (95% CI: -0.64 to -0.05) in the German cohort and 
-0.34 (95% CI: -0.62 to -0.07) in the UK cohort. The parameter regressing the log cumulative 
baseline hazard in the development cohort on the log cumulative baseline hazard in the German 
cohort was 0.83 (95% CI: 0.72-0.93) corresponding to a less steep increase in the German cohort. 
For the Swedish and the UK cohort the corresponding numbers were 0.91 (95% CI: 0.78-1.05) and 
1.00 (95% CI: 0.85-1.15), respectively. Finally, the specification of the linear predictor for all three 
cohorts appeared correct with confidence intervals all including unity.  
      Harrell’s C index for the OS nomogram was 0.787 (95% CI 0.753-0.817), 0.772 (95% CI 0.747-
0.817), and 0.766 (95% CI 0.746-0.788) for 1-, 3-, and 5- years, respectively. Similarly, external 
validation after 1-, 3- and 5- years, gave C-indexes for the Swedish cohort of 0.836 (95% CI 0.775-
0.881), 0.793 (95% CI 0.749-0.833), and 0.780 (95% CI 0.743-0.815); for the German cohort 0.712 
(95% CI 0.655-0.764), 0.722 (95% CI 0.683-0.759), and 0.707 (95% CI 0.671-0.741); and for the 
UK cohort of 0.815 (95% CI 0.775-0.864), 0.797 (95% CI 0.755-0.832), and 0.791 (95% CI 0.751-
0.822). Brier plots for OS are presented in Suppl. Fig. S1 and histograms of the linear predictor 
plots shown in Suppl. Fig. S2.  
 
Progression-free survival 
In total, 540 (41%) patients in the development cohort experienced disease progression or death, 
with 187 (24%) patients in the HPV+/p16+ subgroup vs. 274 (66%) patients in the HPV-/p16- 
subgroup (P < 0.001). Crude cumulative incidence of progression or death in the development 
cohort was at 5 years 28% (95% CI 25–32%) for the HPV+/p16+ patient group and 71% (95% CI 
66–75%) for the HPV-/p16- patient group (Figure 4). In the validation cohorts, 208 (61%) of 344 
patients in the German, 162 (32%) of 503 in the Swedish, and 158 (34%) of 463 in the UK cohort 
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developed disease progression or death. Follow-up times are given in Suppl. Table S1. In the 
multivariable model, the AIC backward selection procedure led to exclusion of the variable UICC-8 
staging and inclusion of the covariates age, gender, combined HPV and p16 status, smoking, T-, N-, 
and M-classification (Table 4).  
 
    The nomogram for prediction of progression-free survival at 1-, 3- and 5 years is shown in Figure 
5. Harrell’s C index of the development cohort was 0.733 (95% CI 0.703-0.760), 0.728 (95% CI 
0.704-0.750), and 0.725 (95% CI 0.703-0.747) at 1, 3, and 5 years. External validation of the 
nomogram for progression-free survival after 1-, 3- and 5- years, gave C-indexes of 0.805 (95% CI 
0.745-0.852), 0.763 (95% CI 0.722-0.802) and 0.764 (95% CI 0.724-0.801), respectively, for the 
Swedish cohort; 0.714 (95% CI 0.663-0.761), 0.711 (95% CI 0.671-0.748), and 0.704 (95% CI 
0.667-0.738), respectively, for the German cohort; and 0.797 (95% CI 0.739-0.842), 0.778 (95% CI 
0.735-0.812), and 0.771 (95% CI 0.731-0.805), respectively, for the UK cohort. The parameter 
regressing the log cumulative baseline hazard in the development cohort on the log cumulative 
baseline hazard in the German cohort was 0.88 (95% CI: 0.69-1.07), in the Swedish cohort 1.16 
(95% CI: 0.97-1.36) and the UK cohort 1.20 (95% CI: 0.99-1.40). The specification of the model 
for all cohorts appeared correct with confidence intervals all including unity. Calibration plots for 
internal and external validation of PFS are shown in Figure 6, Brier plots in Suppl. Fig. S3 and 
histograms of the linear predictor plots in Suppl. Fig. S4.  
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Discussion 
This study presents multinational-validated nomograms for OS and PFS for patients with OPSCC. 
One of the main findings includes the identification of combined HPV-DNA and p16-status as an 
important and independent predictor for OS and PFS. The nomograms performed well in external 
validation across areas with high and low HPV-prevalence. These models may facilitate discussions 
in clinical settings and aid in identifying lower-risk patients that could be candidates for de-
escalation therapy, as well as higher-risk patients eligible for treatment-escalation trials. The online 
nomogram (www.orograms.org) can be used for more precise calculations than drawing lines on the 
nomogram. 
   The significance of the double biomarker can be exemplified in a typical patient case of a male, 
60 years of age, non-smoker, and classified as T2N2M0, UICC-8 stage II. If the tumour is 
HPV+/p16+, the 3- and -5 year OS-estimates are 90% and 84%, respectively. However, if the 
tumour is HPV-/p16+, the 3- and -5 year OS-estimates fall to 72% and 60%, respectively. Similar 
reductions are seen in PFS-estimates when comparing HPV+/p16+ with HPV-/p16+ tumors. 
Although, these numbers are estimates, they underline the importance of evaluating patient-
prognosis using the combined biomarker of HPV and p16. 
   Notably, HPV+/p16+ patients with T1-T2 and N1 tumours could be considered candidates for de-
escalation therapy, as their survival is similar to the background population(Grønhøj Larsen et al, 
2016), and this might avoid some of the morbidity associated with therapy. Our models also 
encourage studies to better understand whether HPV+/p16+ patients with N2 and N3 tumours are 
eligible for de-escalation as well. Notably, at least nine de-escalation treatment trials are on-going 
or finishing(Masterson et al, 2014). Our nomograms are likely to be applicable to these and future 
trials, as we report similar 5-year survival or progression rates as in North America, (Agoston et al, 
2010; Ang et al, 2010; Fakhry et al, 2014) Western, (Hafkamp et al, 2008; Preuss et al, 2008; Junor 
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et al, 2012) Southern, (Rittà et al, 2009) and Northern Europe, (Mellin et al, 2000b; Dahlstrand et 
al, 2005) Australia, (Hong et al, 2010) and China (Zhao et al, 2009).  
    One of the strengths in this study is the joint use of HPV and p16 for scoring tumours. Other 
advantages are the large sizes of the development and validation cohorts all from areas with 
universal, tax-financed health care systems diminishing selection bias. In a previous smaller study 
in a region with very low HPV-prevalence (< 20%), the development cohort was not from a 
population-based, non-selected setting when constructing nomograms for OS and PFS in OPSCC 
patients (Rios Velazquez et al, 2014). A recently published nomogram from the US, also with 
smaller cohorts, mainly included patients from private hospitals, and did not include the important 
double biomarker of HPV and p16 (Fakhry et al, 2017). This study also had difficulties in showing 
the significance of p16 alone for e.g. progression-free survival.  
    In this study, we chose overall survival instead of disease-specific survival as a primary endpoint 
because it represents the cumulative effect of competing diseases, treatment-morbidity, and age on 
patient survival. As disease progression is associated with significantly poorer outcome and 
consequently a decrease in quality of life, we developed a nomogram with PFS as the endpoint. The 
PFS nomogram therefore complements the overall survival nomogram well.  
    Although our training cohort is population based and selection-bias is minimized, the nomograms 
have limitations. With respect to accuracy, the CIs at the various predicted probabilities of 
recurrence should be considered if using these nomograms in clinical settings. The final models 
performed well in calibration and discrimination, but the level (risk of outcomes) is – as expected – 
not identical across cohorts. This is most evident in the German cohort, and this risk should be 
taken into account when using the models. The German cohort might perform worse due to several 
factors; partly a significant lower HPV-prevalence, higher smoking, higher share of patients who 
experience progression, and a greater share of patients in advanced stage (e.g. stage 3 and 4). 
Although this is adjusted for, it should be considered whether these nomograms are best suitable in 
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HPV-high risk areas. A possible other bias in this model is the number of censored patients as 
observed in the crude survival analysis. The Danish, UK and Swedish centers have approximately 
60-70% censorship opposed to the German with merely 45% censored patients.  
These nomograms are only applicable for patients who underwent evaluation at multidisciplinary 
head and neck cancer centres, as performance of the nomograms is likely to be worse for patients 
who do not attend multidisciplinary evaluation.  
     p16 overexpression is a reliable biomarker for high-risk HPV-associated OPSCC(Lewis JR, 
2012; Chernock et al, 2013; Grønhøj Larsen et al, 2014). But notably, p16 overexpression is also 
present in a number of non-HPV-driven tumours probably related to RAS and BRAF mutations 
(Romagosa et al, 2011) although not in KRAS (Prigge et al, 2014). Other head and neck 
carcinomas have proven to be HPV-/p16+ likely related to misconfigurations in the p16-Rb-
cyclin-D1 pathway inducing cell cycle activation in HPV-negative carcinomas (Albers et al, 
2017).  
         The prevalence of HPV-associated OPSCC ultimately depends on the sensitivity and 
specificity detection method employed, and using different methods between cohorts as in this 
study, might lead to discordant results in HPV/p16 testing. All four centers employed different 
p16 and HPV-testing tools, which is a potential shortcoming. All methods cover the most 
relevant HR-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66). However, the 
Ventana in situ method (UK cohort) is highly sensitive but less specific opposed amplification of 
HPV DNA by a general primer PCR (GP5+/6+) with presumed high sensitivity and specificity 
(Danish, Swedish, and German cohort), and the subsequent detection of the PCR products with 
type-specific probes, e.g. bead-based multiplex, might differ. A limitation of this study is also the 
use of different p16-antibodies across centers potentially leading to a discrepancy in p16-
positivity. Preferably, a subset of tumours should be tested with all methods to uncover potential 
shortcomings.  
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    In conclusion, we developed and validated nomograms for OPSCC patients and known HPV-
DNA and p16 status. The nomograms are applicable for both high and low HPV-areas. Combining 
HPV-DNA and p16-status is essential for accurate prognostication. Future work might focus on 
validating our results and incorporating additional prognostic factors including nomograms specific 
for salvage treatment for relapsed disease as well as including outcome measures which have shown 
to influence outcome (i.e. weight loss, education, and anaemia) and outcomes such as 
histopathological evaluations. 
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Tables  
Table 1 Patient characteristic in the four cohorts  
Variable  
Eastern 
Denmark 
Giessen, 
Germany 
Karolinska, 
Sweden 
The Predictr Consortium, 
UK 
Number of patients 1313  344  503  463  
OS (median [IQR]) 3.62 [1.85, 5.00] 3.97 [1.18, 5.00] 5.00 [3.33, 5.00] 3.77 [1.73, 5.00] 
Overall survival (%)     
Censored 888 (63.8) 164 (45.7) 389 (71.9) 420 (62.6) 
Events 503  195 ( 54.3) 151 ( 27.9) 177 (26.4) 
NA 0 (0.0) 0 (0.0) 1 (0.2) 74 (11.0) 
PFS (median [IQR]) 2.74 [1.12, 5.00] 2.48 [0.77, 5.00] 5.00 [2.46, 5.00] 3.59 [1.43, 5.00] 
Progression free survival (%)     
Censored 794 (57.1) 139 (38.7) 364 ( 67.3) 397 (59.2) 
Events 545 (39.2) 220 (61.3) 174 (32.2) 203 (30.3) 
NA 52 (3.7) 0 (0.0) 3 (0.6) 71 (10.6) 
Smoking (%)  
    
Current  509 (38.8)  265 (77.0)  178 (35.4)  183 (39.5)  
Former  532 (40.5)  40 (11.6)  164 (32.6)  156 (33.7)  
Never  272 (20.7)  39 (11.3)  161 (32.0)  124 (26.8)  
Male (%)  947 (72.1)  265 (77.0)  373 (74.2)  340 (73.4)  
Age at diagnosis (median 
[IQR])  
59.81 [53.93, 
66.38]  
58.89 [52.69, 
64.97]  
60.00 [53.00, 
67.00]  
56.00 [50.00, 63.00]  
HPV-DNA and p16 status 
(%)      
HPV-/p16-  411 (31.3)  233 (67.7)  85 (16.9)  141 (30.5)  
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HPV-/p16+  84 (6.4)  23 (6.7)  27 (5.4)  31 (6.7)  
HPV+/p16-  59 (4.5)  21 (6.1)  36 (7.2)  18 (3.9)  
HPV+/p16+  759 (57.8)  67 (19.5)  355 (70.6)  273 (59.0)  
T (%)  
    
T1  278 (21.2)  75 (21.8)  124 (24.7)  85 (18.4)  
T2  614 (46.8)  98 (28.5)  178 (35.4)  184 (39.7)  
T3  296 (22.5)  84 (24.4)  101 (20.1)  100 (21.6)  
T4  125 (9.5)  87 (25.3)  100 (19.9)  94 (20.3)  
N (%)  
    
N0  282 (21.5)  95 (27.6)  101 (20.1)  116 (25.1)  
N1  686 (52.2)  47 (13.7)  94 (18.7)  77 (16.6)  
N2  206 (15.7)  187 (54.4)  287 (57.1)  252 (54.4)  
N3  139 (10.6)  15 (4.4)  21 (4.2)  18 (3.9)  
M1 (%)  15 (1.1)  31 (9.0)  4 (0.8)  3 (0.6)  
Treatment (%)  
    
RT 698 (53.2)  19 (5.5)  292 (58.1)  47 (10.2)  
RT+C 585 (44.6)  121 (35.2)  201 (40.0)  154 (33.3)  
Surgery + RT/C 10 (0.8)  138 (40.1)  0 (0.0)  229 (49.5)  
Surgery 20 (1.5)  52 (15.1)  0 (0.0)  33 (7.1)  
Unspecified curative 
treatment 
0 (0.0)  14 (4.1)  10 (2.0)  0 (0.0)  
UICC8 (%)  
    
I  587 (44.7)  58 (16.9)  97 (19.3)  66 (14.3)  
II  260 (19.8)  63 (18.3)  222 (44.1)  224 (48.4)  
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III  206 (15.7)  50 (14.5)  105 (20.9)  87 (18.8)  
IV  260 (19.8)  173 (50.3)  79 (15.7)  86 (18.6)  
RT: Radiation-therapy; C: chemotherapy 
 
 
 
 
 
 
 
 
Table 2 Overall survival estimates HPV+/p16+ and HPV-/p16- patients  
 Eastern Denmark Karolinska, Sweden Giessen, Germany The Predictr Consortium, UK 
OS HPV+/p16+ HPV+/p16+ HPV+/p16+ HPV+/p16+ 
1-year 95% (93%-96%) 96% (94%-98%) 91% (84%-98%) 97% (95%-99%) 
3-year 86% (84%-89%) 88% (85%-91%) 84% (75%-93%) 87% (83%-91%) 
5-year 80% (77%-83%) 81% (77%-85%) 81% (72%-91%) 82% (77%-87%) 
     
OS HPV-/p16- HPV-/p16- HPV-/p16- HPV-/p16- 
1-year 71% (67%-75%) 69% (60%-80%) 76% (71%-82%) 74% (67%-82%) 
3-year 46% (41%-51%) 48% (39%-60%) 47% (41%-54%) 52% (44%-62%) 
5-year 34% (29%-39%) 38% (29%-49%) 35% (30%-42%) 42% (34%-52%) 
Censored cases n=888 (63.8%) n= 389 (71.9%) n= 164 (45.7%) 
n=420 (62.6%) 
 
OS: Overall survival 
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Table 3 Final model for overall survival in the development cohort (no covariates were removed 
from the full model) 
 
 HR 2.5% 97.5% P 
Age 1.03 1.02 1.04 <0.01 
Gender; female (ref)     
Gender; male 1.19 0.96 1.47 0.12 
HPV-/p16- (ref)     
HPV-/p16+ 1.01 0.63 1.64 0.96 
HPV+/p16- 0.75 0.51 1.10 0.14 
HPV+/p16+ 0.39 0.26 0.58 <0.01 
Smoking, Current (ref)     
Smoking, Former 0.62 0.49 0.77 <0.01 
Smoking Never 0.54 0.38 0.77 <0.01 
UICC8 I (ref)     
UICC8 II 0.97 0.66 1.44 0.88 
UICC8 III 1.46 0.92 2.31 0.11 
UICC8 IV 1.27 0.63 2.56 0.51 
T1 (ref)     
T2 1.39 1.02 1.87 0.03 
T3 1.89 1.34 2.67 <0.01 
T4 2.72 1.79 4.14 <0.01 
N0 (ref)     
20 
 
N1 1.08 0.81 1.43 0.59 
N2 1.40 0.94 2.08 0.10 
N3 1.98 1.29 3.04 <0.01 
M0 (ref)     
M1 2.28 1.28 4.08 0.01 
 
 
 
 
 
 
 
 
 
 
Table 4 Final model for progression-free survival in the development cohort (UICC-8 staging was 
removed from the full model) 
 
 HR 2.5% 97.5% P 
Age 1.01 1.01 1.02 <0.01 
Gender, female (ref)     
Gender, male 1.24 1.02 1.51 0.03 
HPV-/p16- (ref)     
HPV-/p16+ 0.91 0.65 1.26 0.57 
HPV+/p16- 0.75 0.52 1.09 0.13 
HPV+/p16+ 0.41 0.33 0.52 <0.01 
Smoking, Current (ref)     
Smoking, former 0.64 0.52 0.78 <0.01 
Smoking, never 0.63 0.47 0.85 <0.01 
T1 (ref)     
T2 1.43 1.09 1.87 0.01 
T3 1.81 1.36 2.41 <0.01 
T4 3.10 2.27 4.25 <0.01 
N0 (ref)     
N1 1.17 0.92 1.50 0.20 
N2 1.61 1.24 2.09 <0.01 
N3 2.02 1.53 2.66 <0.01 
M0 (ref)     
M1 1.79 1.02 3.13 0.04 
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Figures 
Figure 1 Kaplan-Meier curves depicting overall survival probability for HPV+/p16+ patients vs. 
HPV-/p16- patients.  
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Figure 2 Predictive nomogram for overall survival. The nomogram is used by totalling the points 
identified on the top scale for each independent covariate. The total points scale is used to identify 
the probability of 1-, 3-, and 5-year survival. 
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Figure 3 Calibration for 1-year (top row), 3-year (middle row), and 5-year overall survival. DK: 
Denmark (development cohort).  
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Figure 4 Kaplan-Meier curves depicting progression-free survival probability for HPV+/p16+ 
patients vs. HPV-/p16- patients.  
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Figure 5 Predictive nomogram for progression-free survival. The nomogram is used by totalling the 
points identified on the top scale for each independent covariate. The total points scale is used to 
identify the probability of 1-, 3-, and 5-year survival. 
 
 
 
 
 
 
 
 
Figure 6 Calibration for 1-year (top row), 3-year (middle row), and 5-year progression-free 
survival. DK: Denmark (development cohort) (PFS: Progression-free-survival) 
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Supplementary Tables  
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Suppl. Table S1 Number of patients, events, and median survival for overall- and progression-free 
survival and corresponding confidence interval. Blank boxes means that the probability of survival 
is greater than 50% after 5 years, which implies that the median is not defined. Numbers are with 
censoring after 5 years.  
 
  Overall survival 
  Records events median 0.95 LCL 0.95 UCL 
Eastern Denmark HPV-/p16- 411 257 2.29 1.95 3.05 
Giessen, Germany HPV-/p16- 233 149 2.56 2.09 3.86 
Karolinska, Sweden HPV-/p16- 85 53 2.68 1.39 4.08 
UK HPV-/p16- 141 75 3.35 2.18  
Eastern Denmark HPV+/p16+ 759 131    
Giessen, Germany HPV+/p16+ 67 13    
Karolinska, Sweden HPV+/p16+ 355 67    
UK HPV+/p16+ 273 44    
  Progression-free survival 
  Records events median 0.95 LCL 0.95 UCL 
Eastern Denmark HPV-/p16- 411 274 1.57 1.19 2.08 
Giessen, Germany HPV-/p16- 233 167 1.86 1.48 2.48 
Karolinska, Sweden HPV-/p16- 85 54 1.51 1.07 3.77 
UK HPV-/p16- 141 85 2.21 1.59 3.59 
Eastern Denmark HPV+/p16+ 759 187    
Giessen, Germany HPV+/p16+ 67 15    
Karolinska, Sweden HPV+/p16+ 355 80    
UK HPV+/p16+ 273 53    
 
 
Supplementary figures 
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Suppl. Figure S1 Brier score (plots) for overall survival.  
 
 
 
 
 
 
Suppl. Figure S2 Linear predictor for overall survival 
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Suppl. Figure S3 Brier score (plots) for progression-free survival 
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Suppl. Figure S4 Linear predictor for progression-free survival 
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